Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.59 |
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | NGFR | P08138 | 1/20 | 0.44 |
| ▸ | TYMS | P04818 | 2/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24303138 | 0.83 | PARP1 (0.48) | CHEK1PARP1CA12CA9AR | |
| SCHEMBL5879303 | 0.79 | CHEK1 (0.59) | CHEK1PARP1CA12CA9CDK4 | |
| SCHEMBL5879297 | 0.79 | CHEK1 (0.59) | CHEK1PARP1ARTYMSCDK4 | |
| SCHEMBL5879244 | 0.79 | CHEK1 (0.59) | CHEK1CDK4CCND1 | |
| SCHEMBL5879160 | 0.79 | CHEK1 (0.82) | CHEK1ROCK2 | |
| SCHEMBL5879181 | 0.79 | CHEK1 (0.82) | CHEK1PARP1ROCK2 | |
| SCHEMBL5879238 | 0.76 | PDGFRB (0.62) | CHEK1ROCK2 | |
| Bis-Imide A SCHEMBL31061368 | 0.74 | CHEK1 (1.00) | CHEK1PARP1CA12CA9CDK4 | |
| Bis-Imide A SCHEMBL5879127 | 0.74 | CHEK1 (1.00) | CHEK1PARP1CA12CA9CDK4 | |
| SCHEMBL5342370 | 0.71 | PARP1 (0.58) | PARP1CA12CA9ARNGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7151108-B2 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATORIES SERVIER (FR) | 2006-12-19 | — | — | US | disclosed |
| EP-1411057-B1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | LES LABORATOIRES SERVIER (FR) | 2004-04-22 | — | — | US | disclosed |
| EP-1411057-A1 | [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2004-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077672-A1 | Anticarcinogenic, antiproliferative, and antitumor agents | XDH, TOP2A, TOP1 | CHEK1 943/4885PARP1 120/4885CA12 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.